<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00250120</url>
  </required_header>
  <id_info>
    <org_study_id>1402C-T</org_study_id>
    <nct_id>NCT00250120</nct_id>
  </id_info>
  <brief_title>Pharmacology Study of Aerosolized Liposomal</brief_title>
  <official_title>Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S) - Camptothecin (L9NC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the overall response rate to liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)
      administered by aerosolization in patients with non-small-cell lung cancer (any stage).

      To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days
      per week X 8 weeks, every 10 weeks.

      To perform a pharmacology study of L9NC in the plasma, and the lungs after aerosolization. A
      specific protocol will be written for this part.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, non-randomized Phase II trial of DLPC-9NC administered by aerosol 5
      consecutive days per week for 8 weeks every 10 weeks.

      Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day)
      per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks.

      Patients that have a resectable lung cancer will only receive one course of treatment and
      will be operated on about two weeks after completing the 8-week course.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological examination of lung tissure</measure>
    <time_frame>at surgery</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Diseases</condition>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin</intervention_name>
    <description>delivery mode: inhalation</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients participating in INST 1402C protocol

          -  Phase II Study of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in Patients
             with Advanced (NSCLC) Lung Cancer are eligible if their tumor is resectable with
             curative intent as determined by Dr. Reza Mehran.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire F Verschraegen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2005</study_first_submitted>
  <study_first_submitted_qc>November 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2005</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <name_title>Claire Verschraegen, MD; Principal Investigator</name_title>
    <organization>Universtiy of New Mexico - CRTC</organization>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>L9NC</keyword>
  <keyword>Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Rubitecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

